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ABSTRACT
The focus of bioanalysis employed for the quantitative determination of an active analyte(s) and their metabolite(s) in the biological matrix such as 
plasma, serum, blood, cerebrospinal fluid, and tissues. The extraction of analyte and metabolite in the biological fluids is carried out using different 
separation methods such as protein precipitation, liquid-liquid extraction, and solid phase extraction. Bioanalytical method development and 
validation in the pharmaceutical industry are to provide an assessment and interpretation of pharmacokinetics, pharmacodynamics, toxicokinetics, 
bioavailability/bioequivalence, and therapeutic drug monitoring relationships. This review paper aims to provide a simple and accurate scientific 
background to improve the quality for development and validation of a bioanalytical method for small molecules with industrial technique as per 
regulatory agency requirements (United States Food and Drug Administration, EMEA, International Council for Harmonisation and ANVISA). 
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INTRODUCTION
The bioanalysis is a subdiscipline of analytical chemistry for the 
quantitative measurement of xenobiotics and biotics in biological 
systems and it plays a very important role in drug development, 
the conduct of clinical trials, and in therapeutic drug monitoring 
(TDM). Various analytical procedures have been developed to 
execute bioanalysis, which includes gas chromatography (GS)-flame 
ionization detection, immunoassays, GS-mass spectrometry (MS), high-
performance liquid chromatography (HPLC)-ultraviolet, HPLC-MS 
(HPLC-MS or LC-MS), and HPLC tandem MS (HPLC-MS/MS or LC-MS/
MS) [1,2].
New drug development is a lengthy and costly procedure. It normally 
lasts 15–17 years and roughly 1 out of 5000 compounds may come 
out as marketable drug. The most frequently used techniques in 
bioanalytical studies are HPLC tandem MS (HPLC-MS/MS or LC-MS/
MS). Roles of LC-MS bioanalysis in drug discovery, development, and 
TDM is given in Fig. 1 [3-5].
Bio-analytical validation confirms the high-quality data for regulatory 
submission as well as for the drug discovery and development [6]. 
The first guideline released by the United States Food and Drug 
Administration (USFDA) for the bioanalytical method validation in 
May 2001 which were further amended in May 2012 and presently 
final version released May 2018 [7-9]. National Health Surveillance 
Agency (ANVISA), Brazil released its first bioanalytical guidelines in 
May 2003 in combination with analytical validation guidelines, which 
were further amended in May 2012 [10,11]. European Medicines 
Agency (EMA, European authority) issued its guidelines which became 
effective since February 2012 [12]. Ministry of Health, Labour and 
Welfare MHLW, Japan issued draft guideline for bioanalytical methods 
in 2013 [13]. International Council for Harmonisation (ICH) issued its 
draft guidelines which became since Feb 2019 [14].
Reference standard
Bioanalysis of drugs and their metabolites are carried out using 
samples spiked with calibration (reference) standards and Quality 
Control samples. The reference standard purity of spiked samples can 
affect study results. Hence, a certified analytical reference standard 
of known identity and purity should be used to prepare solutions of 
labeled concentrations. If at all possible, the reference standard should 
be identical to the analyte, not possible; an established chemical form 
(free acid, base, and salt) of known purity can be used. Three types of 
reference standards are used:
i.	 Certified	 reference	 standards	 (e.g.,	 USP	 [U.S.	 Pharmacopoeia]	
standards)
ii. Commercially supplied reference standards obtained from a 
reputable commercial source
iii. Custom synthesized materials with documented purity by an 
analytical laboratory.
The analyte source and batch/lot number, expiry date, certificates of 
analyses available, and internally or externally created confirmation of 
identity and purity of each reference standard. If the reference standard 
expires, should not make stock solutions for analysis with this batch/
lot of reference standard unless the reference standard’s purity is re-
established [9,15].
METHOD DEVELOPMENT
A bioanalytical method is a set of procedures involved in the collection, 
processing, storage, and analysis of biological matrices (e.g.: Plasma, 
urine, cerebrospinal fluid, etc.) for a chemical compound.
Goals for sample preparation [16]
Remove unwanted interferences (proteins, salts, metabolites, 
endogenous substances)
•	 Solubilize analytes [16]
•	 Remove particulates that may block chromatographic tubing
•	 Concentrate analytes to achieve sensitivity gains
•	 Dilute analyte concentrations or solvent strength when outside the 
range of detection
•	 Modify pH to promote or counteract ionization
•	 Exchange the solvent in which the analyte resides (e.g., aqueous to 
a nonpolar solvent)
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•	 Derivatize or complex with a chemical species to improve detection 
sensitivity
•	 Remove an unwanted metabolic functional group (e.g., glucuronide 
conjugate)
•	 Remove proteins and lipids that can cause ion suppression
•	 Hydrolyze large proteins for peptide analysis
•	 Disrupt analyte binding to protein or another component within the 
sample matrix.
Protein precipitation (PPT)
PPT is a common choice for sample preparation method because it 
involves simply a one-step addition of solvent to the sample and is 
considered a universal procedure (requiring no method development). 
The speed of this technique is very attractive to analysts, as well as its low 
cost and time. The high resolving power of LC-MS/MS analytical methods 
generally overcomes the non-selective cleanup procedure. Typical sample 
matrices that are used with PPT techniques are plasma, serum, whole 
blood, tissue homogenates, and in vitro incubation mixtures [88-90].
A general approach to eliminate proteins from a biological sample is 
the addition of an organic solvent (methanol, ethanol, or acetonitrile). 
Typically, a volume of sample matrix (1 part) is diluted with a volume 
of the precipitating agent (2–4 parts), followed by vortex mixing 
and then centrifugation or filtration to isolate or remove the mass of 
precipitated protein. An aliquot of the supernatant or filtrate is injected 
for bioanalysis [16,17].
Liquid-liquid extraction (LLE)
LLE is a technique used to separate analytes from interferences in 
a sample matrix by the act of partitioning between two immiscible 
liquids under the optimal conditions, the analyte in solution will 
preferentially migrate into the organic solvent. At present, liquid 
extraction replaced with advanced and enhanced methods like liquid-
phase microextraction and supported membrane extraction, single 
drop liquid-phase microextraction [16-18].
Solid phase extraction (SPE)
The main goals of SPE are the elimination of interfering matrix 
components and selective concentration and isolation of the analytes.
SPE protocols
Typical SPE protocols for trace analysis involve following steps
1. Wetting and conditioning – to solvate and activate the sorbent to 
retain analytes of interest
2. Sample loading/retention – application of the sample to the cartridge 
(sorbent) where analytes of interest are retained
3. Wash/rinse – any lesser retained interferences are washed off the sorbent
4. Elution – removal of analytes of interest from sorbent into a collection 
tube using a relatively small volume of a suitable solvent (elution solvent).
To ensure optimum target analyte retention and, depending on the 
sorbent chemistry, it may be necessary to pretreat the sample [18,19].
METHOD VALIDATION
Bioanalytical method validation is the process used to establish the 
qualitative and quantitative determination analyte and metabolites in 
the biological matrix.
Types of method validation
Full validation
Full method validation is mentioned by all the regulatory agency 
(USFDA, EMEA, and ANVISA) for the developing and implementing a 
new bioanalytical method for the analysis of new drug entity and or its 
metabolites(s) or biomarkers. Full validation of the revised assay needs 
to perform if quantification of metabolites is added to the existing assay 
or new analyte/metabolite(s) [7,20].
Partial validation
Partial validations evaluate changes in the already validated 
bioanalytical methods. It can range from as little as one intra assay 
Fig. 1: Roles of liquid chromatography- mass spectrometry bioanalysis in pharmaceutical industry
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accuracy and precision (A&P) determination to nearly full validation. 
Raw data on partial validations should be retained at the analytical 
site for inspection when requested. Typical bioanalytical method 
modifications or changes that fall into this category include, but are not 
limited to the following [7,20],
•	 Bioanalytical method transfer between laboratories or analysts
•	 Modification	in	the	analytical	procedure









•	 Limited sample volume/Rare matrices.
Cross-validation
Cross method validation is a comparison of validation parameters when 
two or more bioanalytical methods are used to generate data within a 
similar study or crosswise different studies. Cross-validation needs to 
consider it if sample analysis within a single study is conducted at more 
than one site or more than one laboratory. In cases, cross-validation 
with shared matrix quality control samples and non-pooled subjects 
samples should be conducted at each site or laboratory to establish 
inter-laboratory reliability [21,22]. 
Validation parameters
System suitability
The system suitability test of the chromatographic system was 
performed to confirm the adequate suitability and reproducibility of 
the system before each day of a validation run. A system suitability test 
was performed by injecting six consecutive injections using a standard 
aqueous mixture equivalent to middle concentration of the calibration 
standard curve of analyte and working concentration of ISTD [23].
Acceptance criteria
The % coefficient of variation (CV) for the peak area response ratio was 
found	to	be	≤5.0%	and	that	for	retention	time	was	≤2.0%.
Autosampler carry over test 
This denotes that a compound is getting carried over from one injection 
to the next. The chromatographic system should be tested to evaluate 
the possibility of carry over by injecting mobile phase followed by 
an extracted blank, extracted lower limit of quantification (LLOQ), 
extracted ULOQ, and then once again extracted blank [22,23].
Acceptance criteria
The response of interference at analyte RT should not be more than 
or equal to 20% of extracted LLOQ response for the drug and 5% of 
internal standard response at ISTD RT in a reinjected blank sample 
after extracted ULOQ sample. 
Selectivity/specificity
Selectivity/specificity is the extent to which the method can determine 
a particular analyte of interest in the analyzed matrices without 
interference from endogenous components, internal standard, multiple 
analyte(s), co-administered drug, and concomitant medication drugs.
Process minimum of six individual blank matrix lots including one 
hemolyzed and one lipemic matrix from independent sources as per 
the method with respective lots LLOQ level. The impact of hemolyzed/
lipemic samples or samples from special populations can be included in 
the selectivity assessment. Evaluate the interference in a blank matrix 
by comparing the response at the retention time of analyte(s) and ISTD, 
against LLOQ spiked sample [7,24,25].
Acceptance criteria
•	 Analyte response in STD Blank should not exceed 20% of respective 
LLOQ sample of matrix and LLOQ response should be ±20% of 
nominal concentration
•	 The ISTD response in the STD blank should not exceed 5% of the 
average ISTD responses of the accepted calibrators and QCs
•	 Evaluate the 80% of tested lots are free from interference at the 
retention time of the analyte and internal standard [41-44].
Sensitivity
This is the lowest possible amount of analyte that can be detected 
and distinguished from noise in the instrument with adequate A&P. A 
minimum of six replicates of LLOQ samples shall be analyzed with a 
freshly prepared calibration curve for the sensitivity assessment. The 
LLOQ evaluation shall be done separately or as part of the precision and 
accuracy assessment for the calibration range [7,26].
Acceptance criteria
The	precision	of	LLOQ	samples	should	be	≤20%	and	mean	%	bias	of	
LLOQ samples should be within ±20%. The individual % bias of at least 
67% (4 out of 6) of LLOQ samples should be within ±20%.
Detection limit
According to ICH, it is the lowest concentration of an analyte in a sample 
which can be detected but not necessarily quantified as an exact value. 
According to Conference Report II, it is the lowest concentration of 
an analyte in a sample that the bioanalytical procedure can reliably 
differentiate from background noise [27].
Linearity/calibration curve
The calibration curve also known as the standard curve is the relationship 
between the instrument response and the calibration standards within 
the intended quantitative concentration range. It constructed using 
calibration standards are used to back-calculate the concentrations of 
quality control samples and if applicable (subject) samples [34-40,45].
Calibration curve/linearity shall contain (standard) blank (no analyte, 
no ISD), zero calibrators/standard zero (blank plus ISTD(s)), and at least 
six non-zero calibrator levels covering the quantitation range, including 
LLOQ in every run and evaluate at least 3 calibration curves generated 
using spiked samples. The concentration-response relationship, as well 
as an appropriate weighting scheme and regression equation, should be 
established [28,29].
Acceptance criteria
•	 The accuracy (% bias) of LLOQ/STD-01 from nominal concentration 
should be within ±20% and for standards other than LLOQ; accuracy 
(% bias) should be within ±15%
•	 At least 75% non-zero standards should meet the above criteria, 
including the LLOQ and the calibration standard at the highest 
concentration
•	 The	goodness	for	fit	value	should	be	greater	than	or	equal	to	0.98
•	 Only data points that fail to meet the acceptance criteria shall be 
excluded from the study.
A&P
The precision of the assay was measured by the percentage coefficient 
variation over the concentration range of quality control samples of 
analyte and metabolite during the validation and the accuracy of the 
assay was defined as the absolute value of the ratio of calculated mean 
concentration values of the quality control samples to their respective 
nominal values [90-94].
A&P should be established with at least three independent A&P runs, 
four QC levels per run (LLOQ, LQC, MQC, and HQC), and six replicates 
per QC level. With intra-inter run A&P. A&P experiments shall be 
performed using freshly prepared calibration standards and freshly 
prepared QCs [28-29].
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•	 Accuracy should be within ±15% of the nominal concentrations 
except for LLOQ, where it should be within ±20%
•	 Precision determined at each concentration level should be ±15% 
CV except, ±20% CV at LLOQ
•	 Accuracy: Within-run and between runs: ± 15% of nominal 
concentrations; except ±20% at LLOQ
•	 Precision: Within-run and between runs: ±15% CV, except ±20% CV 
at LLOQ
•	 Analytical runs which met the acceptance criteria will be reported 
and failed runs will be investigated
•	 The failed QCs can be removed from a calculation based on the outlier 
test. The data of runs with and without failed QC’s shall be included 
in the report.
Dilution integrity
Dilution linearity demonstrates the accurate measurement of 
concentrations of spiked samples (i.e., QCs) exceeding the quantitation 
range when serially diluted to within the quantitative assay range. The 
A&P of these diluted (DIQC) QC samples should be performed. Dilutions 
used during the validation shall mimic the expected dilutions in the 
study. Analyze a minimum of six replicates from DIQC samples against 
using the freshly prepared calibration standards along with freshly 
prepared QC samples [7,95-97].
Acceptance criteria
The mean accuracy of QC samples should be within ±15% of the actual 
value after dilution and the precision determined at each dilution level 
should not exceed 15% of the CV.
Recovery
Recovery refers to the extraction efficiency of an analytical method, 
reported as a percentage of the known amount of an analyte carried 
through the sample extraction and processing steps of the method.
Absolute recovery
Absolute recovery is calculated by relating the analyte/ISTD mean 
response found in extracted samples of low, medium, and high QC with 
analyte/ISTD mean response in neat aqueous solutions prepared at the 




Average area response  of
 analyte peak in extracted sample% Absolute recovery 100
Average area response  of analyte 
in aqueoussample at 
corresponding concentration  (3)
Relative recovery
Relative recovery is calculated by relating the analyte/ISTD mean 
response found in extracted samples of low, medium, and high QC 
with analyte/ISTD mean response in post-extraction spiked samples 




Average area response  of analyte 
peak in extracted sample% Relative recovery 100
Average area response  of 
analyte in postextractionspiked 
sample at corresponding concentration
 (4)
Acceptance criteria
The recovery for the analyte(s) is acceptable if % CV is less than 15% for 
low, middle, and high QC concentration, individual recovery and global 
recovery should not be more than 110% [6,30].
Matrix factor
The biological matrix can play a role in affecting the selectivity, sensitivity 
and precision. This happens due to direct or indirect alteration of the 
response of analyte from the unintended interferences present in the 
biological matrix. Matrix factor dived into two types [65-70].
i. Absolute matrix factor
ii. Relative matrix factor.
Matrix factor determined by injecting Un-extracted low and high QC 
samples and the post-extraction spiked low and high QC samples.
Matrix effects can arise from several matrix components including, but 
not limited to:
•	 Endogenous biological components such as phospholipids, 
carbohydrates, and endogenous metabolites (bilirubin)
•	 Residual formulation components from intraperitoneal, intravenous, 
or oral dosing (PO) experiments; for example, polyethylene glycol, 
solutol, polysorbate (Tween 80), etc.
•	 An interaction between the analyte of interest and the matrix, such 
as covalent binding to plasma proteins or the enzymatic degradation 
of a prodrug
•	 Co-eluting drug metabolites, mobile phase additives, and concomitant 
medications.
Acceptance criteria
The % CV of the IS-normalized matrix factor calculated from the matrix 
lots should not be greater than 15% [31-33].
Stability
Stability is a measure of the intactness of an analyte (lack of 
degradation) in a given matrix under specific storage and uses 
conditions relative to the starting material for given time intervals. 
Stability of the analyte in a given matrix should be determined, 
including the effects of sample collection, handling, and storage of the 
analyte [50-54].
Matrix-related stability experiments should compare stability QCs 
against freshly prepared calibration curves and freshly prepared QCs. 
Although the use of freshly prepared calibrators, QCs is the preferred 
approach [55-57], 
Stability should assess in the same matrix as that intended for in-
study samples; however, when the matrix is rare, the use of suitable 
surrogate matrices shall be utilized as per the respective study plan/
study requirement [7,14,34].
The following stability shall be assessed during validation as per 




d. Wet extract stability
e. Dry extract stability
f. Reinjection reproducibility
g. Long-term stability of analyte in matrix
h. Stock/working solution stability
i. Whole blood stability.
Autosampler stability
The stability of the analyte and the internal standard should be assessed 
to cover the maximum period of anticipated subject sample batch run 
time. Place the processed samples in the auto sampler at the desired 
temperature and for the estimated period [72-76].
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Bench-top stability
This is to establish the stability of a molecule for a period based on the 
expected duration that samples will be maintained at room temperature 
in the intended study. The spiked samples (LQC and HQC) it shall be kept 
at room temperature for at least for 6 h or more based on the duration 
of the intended study samples retained at room temperature [46-49].
Freeze-thaw stability
The stability of the analyte(s) in plasma samples during freeze-thaw 
cycles was determined by freezing the samples LQC and HQC in the 
freezer (at –70°C and –20°C) and thawing them at room temperature. 
Analyte stability should be determined after a minimum of three 
freezing and thawing cycles [77-81].
Wet extract stability
Wet extract stability shall be evaluated at room temperature (approx 
25°C) and refrigerator (2-8°C). Select the stability duration based on 
the characteristic of the Analyte(s) and to cover maximum anticipated 
sample processing time for the batch size to be used for subject sample 
analysis.
Dry extract stability
Dry extract stability should be performed only when the method 
includes evaporation step.
Process and store at least five replicates of LQC and HQC samples in a 
refrigerator (2–8° 0–70°C) without reconstitution after drying.
After the intended period, reconstitute and analyze the dry extract 
samples.
Reinjection reproducibility
Reproducibility is the precision between two laboratories. It also 
represents the precision of the method under the same operating 
conditions over a short period. Re-injection reproducibility shall be 
evaluated by re-injecting anyone of the accepted P & A [82-85].
Long-term stability of analyte in matrix
Storage period in long-term stability should exceed the time between 
the first sample collection and the date of the last sample analysis (study 
samples). Long-term stability should be determined by the storage of at 
least six aliquots of each concentration (low, high, and diluted integrated 
QC) under the same conditions of the study samples [86,87].
Stock and working solution stability
The stability of stock and working solutions of analyte and the internal 
standard should be evaluated at room temperature for at least 6 h. % 
Deviation	should	be	≤10%	of	bias.	 If	 the	stock	and	working	solutions	
are refrigerated or frozen for the relevant period, the stability should be 
documented. After completion of the desired storage time interval, the 
stability should be tested by comparing the instrument response with 
that of freshly prepared stock and working solutions [58-61].
Whole blood stability
Whole blood stability is performed to ensure the stability of analyte 
in whole blood during sample collection, centrifugation, and handling, 
until plasma/serum has been separated. This period covers the 
duration taken for separation of plasma/serum during the conduct of 
the study [62-64].
Prepare test whole blood QC pools at LQC and HQC level. Store at room 
temperature/ice bath for 0 (control), 1, and 2 h. Centrifuge the whole 
blood sample and collect the plasma/serum (test matrix) for extraction 
and analysis following the validation method. Inject six replicates for 
each group. Compare the mean instrument response of stability test 
samples to that of the control group [3].
Acceptance criteria
The accuracy (% nominal) at each level should be ± 1S% of the nominal 
value and precision should be ±15% CV for all the above stabilities [7].
Hemolysis effect
Hemolysis effect is performed to ensure that the quantitation of the 
analyte is not affected in the presence of hemolysis of biological matrix 
(plasma and serum). Hemolysis effect was studied by processing six 
replicates of LQC and HQC concentrations spiked in hemolyzed plasma 
along with the calibration standards prepared in biological study 
matrix [3,30].
Lipemic effect 
The lipemic effect is performed to ensure that the quantitation of the 
analyte is not affected in the presence of the fed effect of a biological 
matrix (plasma, serum, and whole blood). The lipemic effect was 
studied by processing six replicates of LQC and HQC concentrations 
spiked in lipemic plasma along with the calibration standards prepared 
in biological study matrix [3,30].
Run size evaluation
Evaluate the run size during method validation, which should include 
the number of samples to be analyzed under a run during actual study 
sample analysis. Establish run-size based on the chromatographic run 
time and analyte stability [98,99].
Ruggedness (robustness)
The robustness of an analytical procedure is a measure of its capacity 
to remain unaffected by small, but deliberate variations in method 
parameter condition such as small changes of pH values, mobile 
phase composition, and temperature and provide an indication of its 
reliability during typical usage. The assessment of robustness should 
be measured during the development phase and depends on the type of 
procedure under study. It should demonstrate the reliability of analysis 
concerning deliberate differences in method parameter conditions [14].
CONCLUSION
Bioanalysis turns into a primary tool to cover each stage of drug 
discovery to preclinical studies and all phases of clinical development. 
It provides not only selecting enhanced drug molecules but moreover 
improving our understanding of safety and pharmacokinetics of the 
drugs. A complete regulated bioanalytical method validation minimally 
obliges three precision and accuracy batch, stability and reproducibility 
experiments. Batch failures during method validation and study sample 
analysis are especially costly in terms of time, effort, and perception. 
The good practice to confirm the method validation is to conduct a 
comprehensive method development steps by way of increase the 
confidence of sponsor with the timely and successful completion of the 
study. GLP is an important issue in regulatory bioanalysis.
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